StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the medical technology company’s stock.
BIOL has been the subject of a number of other research reports. Benchmark reaffirmed a speculative buy rating and set a $0.40 target price on shares of BIOLASE in a research report on Tuesday, May 14th. Maxim Group downgraded shares of BIOLASE from a strong-buy rating to a hold rating in a report on Friday, May 24th.
Check Out Our Latest Analysis on BIOLASE
BIOLASE Stock Down 15.3 %
BIOLASE (NASDAQ:BIOL – Get Free Report) last posted its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%. The business had revenue of $11.56 million for the quarter.
Institutional Trading of BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC increased its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.79% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
See Also
- Five stocks we like better than BIOLASE
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Manufacturing Stocks Investing
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- What is MarketRankā¢? How to Use it
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.